{"id":85891,"date":"2018-12-16T15:02:36","date_gmt":"2018-12-16T23:02:36","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2018\/12\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants"},"modified":"2018-12-28T17:59:01","modified_gmt":"2018-12-29T01:59:01","slug":"united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2018\/12\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants","title":{"rendered":"United Therapeutics to Develop CollPlant Technologies for 3D Bioprinted Lung Transplants"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants2.jpeg\"><\/a><\/p>\n<p>United Therapeutics will license, develop, and commercialize CollPlant Holdings\u2019 recombinant human collagen (rhCollagen) and BioInk technology for 3D bioprinting of solid-organ scaffolds for human transplants, the companies said today, through a collaboration that could generate more than $44 million.<\/p>\n<p>Through its wholly- owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, United Therapeutics has been granted what the companies termed an exclusive license \u201cthroughout the universe\u201d by CollPlant to its technology for producing and using rhCollagen-based BioInk for 3D bioprinted lung transplants.<\/p>\n<p>Lung Biotechnology PBC is a public benefit corporation formed to address the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply.<\/p>\n<p><a href=\"https:\/\/www.genengnews.com\/news\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants\/amp\/?__twitter_impression=true\" target=\"_blank\"><\/a><\/p>\n<div style=\"clear:both;\"><a href=\"https:\/\/www.genengnews.com\/news\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants\/amp\/?__twitter_impression=true\" target=\"_blank\">Read more<\/a><\/div>\n<p><a href=\"https:\/\/www.genengnews.com\/news\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants\/amp\/?__twitter_impression=true\" target=\"_blank\"><br \/>\n<\/a><a href=\"https:\/\/www.genengnews.com\/news\/united-therapeutics-to-develop-collplant-technologies-for-3d-bioprinted-lung-transplants\/amp\/?__twitter_impression=true\" target=\"_blank\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>United Therapeutics will license, develop, and commercialize CollPlant Holdings\u2019 recombinant human collagen (rhCollagen) and BioInk technology for 3D bioprinting of solid-organ scaffolds for human transplants, the companies said today, through a collaboration that could generate more than $44 million. Through its wholly- owned organ manufacturing and transplantation-focused subsidiary Lung Biotechnology PBC, United Therapeutics has been [\u2026]<\/p>\n","protected":false},"author":354,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1489,1503,11],"tags":[],"class_list":["post-85891","post","type-post","status-publish","format-standard","hentry","category-3d-printing","category-bioprinting","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/354"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=85891"}],"version-history":[{"count":1,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85891\/revisions"}],"predecessor-version":[{"id":86210,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/85891\/revisions\/86210"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=85891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=85891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=85891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}